Improving survival rates for patients with acute myeloid leukemia: Impacts of fludarabine/busulfan and antithymocyte globulin as reduced toxicity myeloablative conditioning for matched related donor allo-HCT-Reference-Cited by-同舟云学术

Improving survival rates for patients with acute myeloid leukemia: Impacts of fludarabine/busulfan and antithymocyte globulin as reduced toxicity myeloablative conditioning for matched related donor allo-HCT

Published:2020-11 Issue:4 Volume:68 Page:145-148
ISSN:2452-3186
Container-title:Current Research in Translational Medicine
language:en
Short-container-title:Current Research in Translational Medicine

Author:

Yafour Nabil,Serradj Faiza,Osmani Soufi,Brahimi Mohamed,Bouhass Rachid,Arabi Abdessamad,Bazarbachi Ali,Bekadja Mohamed Amine

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference15 articles.

1. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial;Rambaldi;Lancet Oncol,2015

2. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study

3. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine;Lee;J Clin Oncol,2013

4. Antilymphocyte globulin for prevention of chronic graft-versus-host disease;Kroger;N Engl J Med,2016

5. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS;de Lima;Blood,2004

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial;Blood Cancer Journal;2024-02-19